Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Will oral antithrombin agents replace warfarin?

P R Sinnaeve, F J Van de Werf

    Heart (British Cardiac Society)
    |July 16, 2004
    PubMed
    Summary

    Ximelagatran, a new oral direct thrombin inhibitor, offers stroke prevention comparable to warfarin for non-valvular atrial fibrillation patients. It also shows promise as an add-on therapy with aspirin post-acute coronary syndrome.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A contemporary look at pericardiocentesis.

    Trends in cardiovascular medicine·2018
    Same author

    Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.

    Journal of internal medicine·2011
    Same author

    The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.

    Journal of thrombosis and haemostasis : JTH·2008
    Same author

    Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2.

    European heart journal·2007
    Same author

    Acute ST-elevation myocardial infarction.

    Acta clinica Belgica·2007
    Same author

    Relation between different methods for analysing ST segment deviation and infarct size as assessed by positron emission tomography.

    Heart (British Cardiac Society)·2004

    Area of Science:

    • Cardiology
    • Pharmacology
    • Thrombosis Research

    Background:

    • Non-valvular atrial fibrillation poses a significant stroke risk.
    • Warfarin is a standard anticoagulant therapy, but requires monitoring.
    • Acute coronary syndrome necessitates secondary prevention strategies.

    Discussion:

    • Ximelagatran demonstrates non-inferiority to warfarin in preventing strokes in non-valvular atrial fibrillation.
    • The direct thrombin inhibitor shows potential as an adjunct therapy to aspirin in managing patients after acute coronary syndrome.
    • This suggests a new therapeutic option for cardiovascular disease management.

    Key Insights:

    • Ximelagatran provides equivalent stroke prevention to warfarin in non-valvular atrial fibrillation.
    • Ximelagatran may enhance aspirin's efficacy in acute coronary syndrome patients.
    • Direct thrombin inhibitors represent a viable alternative to traditional anticoagulants.

    Outlook:

    • Further research may explore long-term efficacy and safety profiles of ximelagatran.
    • Ximelagatran could offer a more convenient oral anticoagulation option.
    • Its role in combination therapy for cardiovascular prevention warrants additional investigation.

    Related Experiment Videos